People familiar with the matter told Politico in a Dec. 6 report that the administration will not endorse widespread use of the policy and isn’t planning to target any individual medicines. A day later, the White House released a framework recommending the factors federal agencies should consider when determining when to use march-in rights, which, for the first time, specifies that a medication’s price can be a factor in determining whether to break a patent and share it with other drugmakers.
The move marks the Biden administration’s latest push to lower drug prices, a key part of President Joe Biden’s healthcare agenda and reelection campaign.
“We’ll make it clear that when drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” Lael Brainard, a national economic adviser to the White House, said in a Dec. 6 press call, according to CNBC.
The Commerce Department issued the proposed framework and will accept public comment for 60 days, CNBC reported. Pharmaceutical companies have long argued that march-in rights, which have never been used before, would disincentivize the development of new drugs.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.